Jump to: Authorized Access | Attribution | Authorized Requests

Study Description

Tumors from 383 newly diagnosed diffuse large B cell lymphoma were included in this study. Tumor DNA was extracted from formalin-fixed, paraffin embedded (FFPE) tissue sections, germline DNA was extracted from blood, and whole exome sequencing (WES) of all samples (n=340 tumor normal pairs) was performed using the Agilent SureSelect XT AllExon v5 + UTR kit and sequencing was carried out on an Illumina NovaSeq, 100 x 2 paired end reads. Tumor RNA (n=321) was extracted from formalin-fixed, paraffin embedded (FFPE) tissue sections and RNA sequencing was performed using the Illumina TruSeq RNA Exome Kit (Illumina) for library preparation, sequencing platform HiSeq 4000, 100 x 2 paired end reads.

Authorized Access
Publicly Available Data
Study Inclusion/Exclusion Criteria
Inclusion critieria included a diagnosis of DLBCL and enrollment onto the Molecular Epidemiology Resource (MER) of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence (SPORE)
Selected Publications
Diseases/Traits Related to Study (MeSH terms)
Authorized Data Access Requests
Study Attribution
  • Principal Investigator
    • Anne J. Novak. Mayo Clinic, Rochester, MN, USA.
  • Funding Sources
    • R01CA212162-01A1. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
    • P50 CA97274. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
    • U01 CA195568. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.